Found: 36
Select item for more details and to access through your institution.
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
- Published in:
- Supportive Care in Cancer, 2013, v. 21, n. 9, p. 2437, doi. 10.1007/s00520-013-1808-5
- By:
- Publication type:
- Article
Chronic lymphocytic leukemia presenting in association with aplastic anemia.
- Published in:
- American Journal of Hematology, 2002, v. 71, n. 4, p. 323, doi. 10.1002/ajh.10226
- By:
- Publication type:
- Article
Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States.
- Published in:
- Patient Preference & Adherence, 2022, v. 16, p. 573, doi. 10.2147/PPA.S345906
- By:
- Publication type:
- Article
Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer.
- Published in:
- 2006
- By:
- Publication type:
- Letter
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
- Published in:
- European Journal of Haematology, 2023, v. 110, n. 5, p. 564, doi. 10.1111/ejh.13937
- By:
- Publication type:
- Article
Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma.
- Published in:
- Oncology & Therapy, 2016, v. 4, n. 2, p. 287, doi. 10.1007/s40487-016-0034-y
- By:
- Publication type:
- Article
Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis Revisited.
- Published in:
- Advances in Hematology, 2012, p. 1, doi. 10.1155/2012/801495
- By:
- Publication type:
- Article
Precursor T Cell Acute Lymphoblastic Lymphoma Presenting as Bilateral Facial Nerve Palsy.
- Published in:
- Chemotherapy (0009-3157), 2010, v. 56, n. 3, p. 258, doi. 10.1159/000316847
- By:
- Publication type:
- Article
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 3, p. e171, doi. 10.1016/j.clml.2022.12.003
- By:
- Publication type:
- Article
P-225: A first-in-human study of FOR46 in patients with triple refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S164, doi. 10.1016/S2152-2650(21)02352-1
- By:
- Publication type:
- Article
P-064: Heterogeneity of bone marrow biopsy and bone marrow aspirate (BMA) in patients with heavily pretreated relapsed/refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S73, doi. 10.1016/S2152-2650(21)02198-4
- By:
- Publication type:
- Article
A Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma who have been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e246, doi. 10.1016/j.clml.2019.09.408
- By:
- Publication type:
- Article
A Phase 1b/2a Study of the CELMoD Iberdomide (CC-220) in Combination With Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e52, doi. 10.1016/j.clml.2019.09.080
- By:
- Publication type:
- Article
A tale of two paradigms: fixed duration vs continuous therapy in routine clinical practice: An INSIGHT MM study analysis of duration of therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e4, doi. 10.1016/j.clml.2019.09.006
- By:
- Publication type:
- Article
HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S329, doi. 10.1016/j.clml.2019.07.318
- By:
- Publication type:
- Article
A Global Treatment Standard in Multiple Myeloma (MM) Remains Elusive Despite Advances in Care over 15 years: First Results from INSIGHT MM, the Largest Global Prospective, Observational MM Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S247, doi. 10.1016/j.clml.2018.07.146
- By:
- Publication type:
- Article
Organ Biomarker Responses in Patients With Light Chain Amyloidosis Treated With NEOD001 Are Independent of Previous Hematologic Response.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e97, doi. 10.1016/j.clml.2017.03.175
- By:
- Publication type:
- Article
NEOD001 Demonstrates Organ Biomarker Responses in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Results From a Phase 1/2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e22, doi. 10.1016/j.clml.2017.03.038
- By:
- Publication type:
- Article
Global, Prospective, Non-interventional, Observational Study of Disease Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma (MM) Patients (pts): The INSIGHT MM Study (NCT02761187).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e79, doi. 10.1016/j.clml.2017.03.144
- By:
- Publication type:
- Article
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Circular RNAs in acute myeloid leukemia.
- Published in:
- Molecular Cancer, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12943-021-01446-z
- By:
- Publication type:
- Article
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
A phase II trial of BAY 43-9006 (sorafenib) ( NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
- Published in:
- Cancer Medicine, 2014, v. 3, n. 5, p. 1275, doi. 10.1002/cam4.276
- By:
- Publication type:
- Article
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 4, p. 549, doi. 10.1111/bjh.15969
- By:
- Publication type:
- Article
Daratumumab proves safe and highly effective in AL amyloidosis.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 2, p. 342, doi. 10.1111/bjh.15455
- By:
- Publication type:
- Article
The difficult business of assessing new therapies for smouldering multiple myeloma.
- Published in:
- 2018
- By:
- Publication type:
- Editorial
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma ( NPI-0052-107): final study results.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 1, p. 41, doi. 10.1111/bjh.14987
- By:
- Publication type:
- Article
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.
- Published in:
- Cancer (0008543X), 2010, v. 116, n. 16, p. 3807, doi. 10.1002/cncr.25139
- By:
- Publication type:
- Article
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 2, p. 358, doi. 10.1002/cam4.4451
- By:
- Publication type:
- Article
Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
- Published in:
- Current Hematologic Malignancy Reports, 2006, v. 1, n. 3, p. 141, doi. 10.1007/s11899-996-0002-y
- By:
- Publication type:
- Article
PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.
- Published in:
- Cancers, 2022, v. 14, n. 1, p. 160, doi. 10.3390/cancers14010160
- By:
- Publication type:
- Article
Myonecrosis in Sickle Cell Anemia--Overlooked and Underdiagnosed.
- Published in:
- 2010
- By:
- Publication type:
- Case Study
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 9, p. 2325, doi. 10.1007/s00277-021-04534-8
- By:
- Publication type:
- Article
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma.
- Published in:
- Blood & Lymphatic Cancer: Targets & Therapy, 2017, p. 53, doi. 10.2147/BLCTT.S82444
- By:
- Publication type:
- Article